7A0S
50S Deinococcus radiodurans ribosome bounded with mycinamicin I
7A0S の概要
エントリーDOI | 10.2210/pdb7a0s/pdb |
分子名称 | RNA (2732-MER), 50S ribosomal protein L15, 50S ribosomal protein L16, ... (36 entities in total) |
機能のキーワード | complex, npet, macrolide, a2058, antibiotic |
由来する生物種 | Deinococcus radiodurans R1 詳細 |
タンパク質・核酸の鎖数 | 28 |
化学式量合計 | 1337466.16 |
構造登録者 | Breiner, E.,Eyal, Z.,Matzov, D.,Halfon, Y.,Cimicata, G.,Rozenberg, H.,Zimmerman, E.,Bashan, A.,Yonath, A. (登録日: 2020-08-10, 公開日: 2021-08-18, 最終更新日: 2024-01-31) |
主引用文献 | Breiner-Goldstein, E.,Eyal, Z.,Matzov, D.,Halfon, Y.,Cimicata, G.,Baum, M.,Rokney, A.,Ezernitchi, A.V.,Lowell, A.N.,Schmidt, J.J.,Rozenberg, H.,Zimmerman, E.,Bashan, A.,Valinsky, L.,Anzai, Y.,Sherman, D.H.,Yonath, A. Ribosome-binding and anti-microbial studies of the mycinamicins, 16-membered macrolide antibiotics from Micromonospora griseorubida. Nucleic Acids Res., 49:9560-9573, 2021 Cited by PubMed Abstract: Macrolides have been effective clinical antibiotics for over 70 years. They inhibit protein biosynthesis in bacterial pathogens by narrowing the nascent protein exit tunnel in the ribosome. The macrolide class of natural products consist of a macrolactone ring linked to one or more sugar molecules. Most of the macrolides used currently are semi-synthetic erythromycin derivatives, composed of a 14- or 15-membered macrolactone ring. Rapidly emerging resistance in bacterial pathogens is among the most urgent global health challenges, which render many antibiotics ineffective, including next-generation macrolides. To address this threat and advance a longer-term plan for developing new antibiotics, we demonstrate how 16-membered macrolides overcome erythromycin resistance in clinically isolated Staphylococcus aureus strains. By determining the structures of complexes of the large ribosomal subunit of Deinococcus radiodurans (D50S) with these 16-membered selected macrolides, and performing anti-microbial studies, we identified resistance mechanisms they may overcome. This new information provides important insights toward the rational design of therapeutics that are effective against drug resistant human pathogens. PubMed: 34417608DOI: 10.1093/nar/gkab684 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (3.22 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
